Area of research
Cancer Research · Oncology · breast cancer drug design
Research interest
Research interests include Breast Cancer Treatment Studies, Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, and Cancer Immunotherapy and Biomarkers.
Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.
Invasive lobular and ductal breast cancers: a systematic review and metanalysis in association with BRCA1/2 mutation status.
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact
Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status
Current controversies in the use of Oncotype DX in early breast cancer
Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group
Clinical Behavior of Breast Cancer in Young <i>BRCA</i> Carriers and Prediagnostic Awareness of Germline <i>BRCA</i> Status.
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.
Underserved Patient Populations With Metastatic Breast Cancer: A Review of Progress and Remaining Challenges.
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.
Comprehensive Diagnostic and Therapeutic Approaches for Estrogen Receptor-Low Breast Cancer: A Multidisciplinary Perspective From Oncologists and Pathologists.
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer.
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment
The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy.
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow.
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit.
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit